710 Keynote-B59: dose escalation of a phase 1/2 first-in-human, open-label study of GI-101, a novel immunocytokine combining CD80-IL2v, in combination with pembrolizumab in advanced solid tumors

Ítems similars

• 710 Keynote-B59: dose escalation of a phase 1/2 first-in-human, open-label study of GI-101, a novel immunocytokine combining CD80-IL2v, in combination with pembrolizumab in advanced solid tumors
  per: John Powderly, et al.
  Publicat: (2023-11-01)
• 1062 GI-102, a novel CD80-IgG4-IL2v3 fusion protein driving lymphocyte expansion and anti-cancer potential through regulation of immune cells in the tumor microenvironment
  per: Jihyun Kim, et al.
  Publicat: (2023-11-01)
• TAS-102 (trifluridine/tipiracil) plus bevacizumab versus TAS-102 alone as salvage treatment options for metastatic colorectal cancer in routine clinical practice
  per: Ji Eun Shin, et al.
  Publicat: (2024-09-01)
• Utilizing Immunocytokines for Cancer Therapy
  per: Erin Runbeck, et al.
  Publicat: (2021-03-01)
• 1072 GI-108, a novel bispecific fusion protein augments anti-tumor immunity by alleviating immunosuppressive adenosine pathway in CD8+ T cells
  per: Kyungwha Lee, et al.
  Publicat: (2023-11-01)